Trial · NCT03551821
Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
NCT03551821, Phase 2, Completed, Aclaris Therapeutics, Inc.; results first posted 2019-12-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata. Trials, record NCT03551821. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03551821
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
- NCT number
- NCT03551821
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Interventions
- ATI-50002
- First posted
- 2018-06-11
- Last updated
- 2019-12-11
- Results first posted
- 2019-12-11
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinician's Eyebrow Assessment | Six months | Determination of the amount of hair in the affected area. Clinician's Eyebrow Assessment Grade Descriptor 0 No eyebrow hair: No terminal hairs are visible in the affected area(s) 1. A little eyebrow hair: Occasional terminal hairs are visible in the affected area(s) 2. Some eyebrow hair: Numerous terminal hairs are visible in the affected area(s) 3. Most eyebrow hair: Mostly complete eyebrow regrowth with terminal hair in the affected area(s) 4. Full eyebrow hair: Complete eyebrow regrowth with terminal hair in the affected area(s) |
| Secondary | Subject's Eyebrow Assessment | Six months | Determination of the amount of hair in the affected area. Subject's Eyebrow Assessment Grade Descriptor 0 No eyebrow hair: No thick, coarse hairs are visible in the affected area(s) 1. A little eyebrow hair: A few thick, coarse hairs are visible in the affected area(s) 2. Some eyebrow hair: Numerous thick, coarse hairs are visible in the affected area(s) 3. Most eyebrow hair: The majority of the affected area(s) of the eyebrow is covered in thick, coarse hairs 4. Full eyebrow hair: The affected area(s) of the eyebrow is fully covered in thick, coarse hairs |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Clinician's Eyebrow Assessment | Six months | score on a scale | NUMBER | |
| SECONDARY | Subject's Eyebrow Assessment | Six months | score on a scale | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinician's Eyebrow Assessment | ATI-50002 Topical Solution | 0 | score on a scale | ||
| Subject's Eyebrow Assessment | ATI-50002 Topical Solution | 0 | score on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | ATI-50002 Topical Solution | 1 | |
| Overall Study | COMPLETED | ATI-50002 Topical Solution | 1 | |
| Overall Study | NOT COMPLETED | ATI-50002 Topical Solution | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | ATI-50002 Topical Solution | 0 | 1 |
| Total, other adverse events | ATI-50002 Topical Solution | 0 | 1 |
| Total, serious adverse events | ATI-50002 Topical Solution | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03551821
GET https://conductscience.org/api/trials/v1/NCT03551821/registered